AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dicuonzo, G.
Right arrow Articles by Beall, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dicuonzo, G.
Right arrow Articles by Beall, B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2002, p. 3987-3990, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.3987-3990.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Erythromycin-Resistant Pharyngeal Isolates of Streptococcus pyogenes Recovered in Italy

Giordano Dicuonzo,1,2 Ersilia Fiscarelli,3 Giovanni Gherardi,1 Giulia Lorino,4 Fabrizio Battistoni,1 Simona Landi,3 Marina De Cesaris,1 Tommasangelo Petitti,2 and Bernard Beall5*

Department of Laboratory Medicine,1 Hospital Infection Control Program, Università Campus Bio-Medico,2 Servizio di Medicina di Laboratorio, Ospedale Bambino Gesù,3 Istituto di Microbiologia, Università La Sapienza, Rome, Italy,4 WHO Collaborating Center for Streptococcal Research, Respiratory Diseases Branch, Centers For Disease Control and Prevention, Atlanta, Georgia 303335

Received 2 January 2002/ Returned for modification 11 April 2002/ Accepted 10 September 2002


   ABSTRACT
Top
 Abstract
Text
 References
 
Three classes of macrolide resistance phenotypes and three different erythromycin resistance determinants were found among 127 erythromycin-resistant group A streptococcal (GAS) isolates recovered from 355 (35.8%) pediatric pharyngitis patients in Rome, Italy. According to emm and sof sequence typing results, erythromycin-resistant isolates comprised 11 different clonal types. Remarkably, 126 of the 127 macrolide-resistant isolates were serum opacity factor (sof) gene positive. These data suggest a strong association between macrolide resistance and the presence of sof among GAS isolates recovered from Italian pediatric pharyngitis patients.


   TEXT
Top
 Abstract
 Text
References
 
Group A streptococci (GAS) have remained susceptible to benzylpenicillin; however, macrolides are preferred by some physicians (2, 39). Recently, a dramatic increase in macrolide-resistant GAS has been documented in several countries, including Italy (1, 2, 9, 10).

In GAS, macrolide resistance is conferred by the 23S rRNA methylase genes erm(B) (7) and erm(TR) (34) [now considered a variant of erm(A) (31)], as well as by the efflux determinant mef(A) (8, 36). These erm genes often confer inducible resistance to macrolides, lincosamides, and streptogramin B (iMLSB resistance), but also may encode constitutive MLSB (cMLSB) resistance due to upstream attenuator sequence alterations. mef(A) encodes resistance to erythromycin (and other 14- or 15-member ring macrolides), while the organism remains susceptible to clindamycin (and other lincosamides) and streptogramin B (8).

Previous pulsed-field gel electrophoresis (PFGE) work demonstrated that macrolide-resistant GAS isolates in Italy are polyclonal, with a few clones of undefined strain types predominating (17, 30). This study identifies the macrolide resistance genes and strain types, as defined by variable gene sequence typing (VGST), of erythromycin-resistant GAS strains in Rome, Italy.

The isolates consisted of two groups. One hundred nine pediatric pharyngitis GAS isolates were collected in spring 2000 at Ospedale Bambino Gesù in Rome and genotyped by PFGE and VGST (of emm and sof), as described previously (13). In the present study, these isolates were tested for macrolide resistance and were found to consist of 41 macrolide-resistant isolates and 68 macrolide-sensitive isolates (Table 1). A second group of 86 erythromycin-resistant GAS isolates were screened from 246 consecutive pharyngitis isolates at the same hospital during October to December 2000. Thus, a total of 127 macrolide-resistant isolates (Table 2) were found among 355 isolates. This resistance frequency (35.7%) is consistent with previous results in Italy (1, 2, 9, 10, 32).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Distribution of erythromycin resistance and sensitivity among 109 pharyngeal GAS isolates representing 21 different genotypesa

 

View this table:
[in this window]
[in a new window]
  		TABLE 2. Distribution of sequence types (emm and sof), macrolide resistance genes, and macrolide resistance phenotypes among 127 erythromycin-resistant GAS isolates isolated in Italy

 
Sensitivity testing was done with the Etest (AB BIODISK, Solna, Sweden) according to the manufacturer's instructions and was verified by disk diffusion according to the National Committee for Clinical Laboratory Standards (NCCLS) guidelines (25). The erythromycin-clindamycin double-disk test was applied as described previously (17) by a modification of a previous method (33) employing disks of erythromycin (30 µg) and clindamycin (10 µg) (Oxoid, Ltd., Basingstoke, United Kingdom). If there was no inhibition zone around both disks, the result was simply interpreted as resistance (MLS), since this method may not detect inducibility by clindamycin. Blunting of the inhibition zone around the clindamycin disk proximal to the erythromycin disk was considered inducible resistance (iMLS), and susceptibility to clindamycin with no blunting in the inhibition zone proximal to the erythromycin disk indicated the M phenotype.

A multiplex PCR employing AmpliTaq Gold (Perkin-Elmer, Roche Molecular Systems, Branchburg, N.J.) was used to amplify regions of erm(B), erm(A)/erm(TR), and mef(A) as described previously (17, 34, 35). emm and sof sequence types were obtained as described previously (3, 4) for the 109 isolates depicted in Table 1 (13), as well as an additional 86 erythromycin-resistant isolates (in Table 2, including 41 resistant isolates from Table 1).

The macrolide resistance phenotypes, resistance determinants, and VGST results are shown in Table 2. VGST (13) and erythromycin susceptibility (this work) of the 109-isolate set consisting of macrolide-resistant and -sensitive isolates are shown in Table 1. These 109 isolates consisted of 79 sof (serum opacity factor gene)-positive isolates (14 M protein gene [emm] types) and 30 sof-negative isolates (7 emm types). The 41 macrolide-resistant isolates represented 8 different emm sequence types, 7 of which are typically sof gene positive (4, 11, 20, 22, 29). While 40 of the 79 sof-positive isolates (50.6%) were macrolide-resistant, only 1 of the 30 (3.3%) sof-negative isolates was resistant.

Eleven emm types of the 22 found accounted for all macrolide-resistant isolates (Table 2). The majority of these isolates were within types emm12 [21 with MLSB resistance and 13 containing mef(A)], emm89 [20 with iMLSB resistance, one of which also contained mef(A)], emm28 (10 with iMLSB and 3 with MLSB resistance), and emm22 (6 with MLSB and 2 with iMLSB resistance).

The erm(B) determinant was found in 66 of the 127 erythromycin-resistant isolates, and about half were clearly iMLSB (Table 2). Forty of the 44 erythromycin-resistant, mef(A)-positive isolates that were clindamycin sensitive occurred within types emm4, emm12, and emm2. Inducible MLSB resistance conferred by erm(A)/erm(TR) was found only within type emm77 (16 isolates).

Five types (emm12, emm89, emm4, emm28, and emm5.3) consisted of both macrolide-resistant and macrolide-sensitive isolates among the set of 109 isolates comprised of both resistant and sensitive isolates (Table 1). All 68 erythromycin-sensitive isolates, representing 18 emm types, were PCR negative for mef(A), erm(B), and erm(A)/erm(TR). Thirteen of these 18 emm types consisted entirely of macrolide-sensitive isolates (42 isolates).

Type emm89, emm77, emm4, emm44/61, emm11, and emm118, isolates infrequently contain sof genes that diverge extensively from the emm type reference strains and encode serologically distinct opacity factor proteins (4). The sof sequences from the isolates within the types investigated here were 98 to 100% identical to the corresponding sof sequences from the corresponding CDC emm type reference strains. The classical serotype M44 and M61 reference strains share the same emm sequence and M serotypes, yet contain dissimilar sof genes (4). The single type emm44/61 isolate described here is of the strain M44 lineage, since it contains the sof44 sequence.

These data are consistent with previous results indicating that macrolide resistance occurs at a high frequency (about 35%) in GAS pharyngitis isolates recovered in Italy (1, 2, 9, 10, 32). In this study, 64 to 100% of isolates within the common types emm12, emm77, and emm89 were macrolide resistant (Table 1). In contrast, population-based analysis of 496 pharyngitis GAS isolates during 1998 in Quebec, Canada, revealed an incidence of erythromycin resistance of 4.6%, with no resistance detected within types M12, M77, and M89 isolates (40). The majority of the resistant isolates were type M28, all of which harbored erm(A)/erm(TR). Again, this result differs from our results, in which all 14 type emm28 macrolide-resistant isolates carried either erm(B) or mef(A) (Table 2). There has been a 100% correlation between the M28 serotype and the sequence type emm28 from isolates recovered from various countries (2, 4), and based on PFGE (G. Gherardi and B. Beall, unpublished data) and multilocus sequencing data (13, 14), these isolates appear to constitute a clone. From the accumulated data, it is clear that there are distinct geographic differences in both the frequency and the genetic basis of macrolide resistance within individual clonal types.

We found that macrolide resistance within our sample set of 127 resistant isolates, with the exception of a single erm(B)-positive type emm5.3 isolate, was restricted to sof-positive strains (Table 2) which have been estimated to comprise about 65% of invasive and noninvasive GAS isolates recovered in the United States (B. Beall, unpublished data). Analysis of the published literature concerning macrolide resistance in GAS revealed similar results in Chile, Canada, Finland, Germany, Spain, and Sweden in that each study primarily described macrolide resistance in sof-positive types (including types M2, M4, M11, M12, M22, M28, M58, M73, M75, and M77) (6, 12, 19, 21, 27, 28, 40). (For a compilation of sof PCR-positive types and opacity factor-positive types, see references 4 and 20.) These studies along with our work indicate that macrolide resistance is widespread among sof-positive GAS strains of many different clonal types and that resistant GAS within types emm2, emm4, emm12, emm28, emm75, and emm77 are geographically widely distributed. (Although emm12 isolates are opacity factor negative [20], they are sof PCR positive [4]). However, in at least one instance, a localized outbreak of pharyngitis within the United States has been due to a sof-negative, erythromcin-resistant type emm6 strain (23). To our knowledge, our work is the first documentation of macrolide resistance within types emm89, emm44/61, emm9, and emm5 (emm5.3).

Sof is a fibronectin-binding protein that appears to contribute to virulence (11). Differences in binding specificities could effect physical separation of the two broad divisions (sof negative and sof positive) of GAS strains, preventing horizontal transfer events (such as transfers of macrolide resistance determinants) between them. There is circumstantial evidence of natural barriers between sof-negative and sof-positive GAS strains preventing recombination at the mga locus. emm sequences are generally phylogenetically divisible into sof-positive and -negative types (16, 38, 41), even though studies of mga loci have revealed mosaic structures of emm and emm-like genes indicative of intraspecies horizontal recombination events (5, 42).

One study found that the proportion of prtF1-containing strains was much higher among erythromycin-resistant isolates than within susceptible isolates (15). The prtF1 gene encodes another fibronectin-binding protein (37) that appears to be required for efficient entry of GAS into epithelial cells (24). Although limited data indicate that prtF1 is most often present among sof-positive strains (serotypes M28, M62, M12, M49, M9, and M2 and sof sequence type sof75) (22, 26) and may be absent in type emm1 isolates (26), prtF1 has also been found among the sof-negative serotypes M3 and M6 (18, 26). It will be interesting to determine the association between prtF, sof, and other genes encoding extracellular matrix binding proteins with erythromycin resistance in GAS.


   ACKNOWLEDGMENTS
 
This work was supported by a grant from the Italian Ministero della Salute Progetto di Ricerca 99/02/P/498.


   FOOTNOTES
 
* Corresponding author. Mailing address: WHO Collaborating Center for Streptococcal Research, Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333. Phone: (404) 639-1237. Fax: (404) 639-3123. E-mail: bbeall{at}cdc.gov. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Avanzini, C., K. Bosio, G. Volpe, G. Dotti, and D. Savoia. 2000. Streptococcus pyogenes collected in Torino (northwest Italy) between 1983 and 1998: survey of macrolide resistance and trend of genotype by RAPD. Microb. Drug Resist. 6:289-295.[Medline]
  2. Bassetti, M., G. Manno, A. Collidà, A. Ferrando, G. Gatti, E. Ugolotti, M. Cruciani, and D. Bassetti. 2000. Erythromycin resistance in Streptococcus pyogenes in Italy. Emerg. Infect. Dis. 6:180-183.[Medline]
  3. Beall, B., R. R. Facklam, and T. Thompson. 1996. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J. Clin. Microbiol. 34:953-958.[Abstract]
  4. Beall, B., G. Gherardi, M. Lovgren, R. R. Facklam, B. A. Forwick, and G. J. Tyrrell. 2000. emm and sof gene sequence variation in relation to serological typing of opacity-factor-positive group A streptococci. Microbiology 147:1195-1209.
  5. Bessen, D. E., and S. K. Hollingshead. 1994. Allelic polymorphism of emm loci provides evidence for horizontal gene spread in group A streptococci. Proc. Natl. Acad. Sci. USA 91:3280-3284.[Abstract/Free Full Text]
  6. Brandt, C. M., M. Honscha, N. D. Truong, R. Holland, B. Hövener, A. Bryskier, R. Lütticken, and R. R. Reinert. 2001. Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany. Microb. Drug Resist. 7:165-170.[CrossRef][Medline]
  7. Ceglowski, P., and J. C. Alonso. 1994. Gene organization of the Streptococcus pyogenes plasmid pDB101: sequence analysis of the orf eta-copS region. Gene 145:33-39.[CrossRef][Medline]
  8. Clancy, J., J. Petitpas, F. Dib-hajj, W. Yuan, M. Cronan, A. V. Kamath, J. Bergeron, and J. A. Retsema. 1996. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol. Microbiol. 22:867-879.[CrossRef][Medline]
  9. Cornaglia, G., M. Ligozzi, A. Mazzariol, L. Masala, G. Lo Cascio, G. Orefici, and R. Fontana. 1998. Resistance of Streptococcus pyogenes to erythromycin and related antibiotics in Italy. Clin. Infect. Dis. 27:S87-S92.
  10. Cornaglia, G., M. Ligozzi, A. Mazzariol, M. Valentini, G. Orefici, and R. Fontana. 1996. Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. Emerg. Infect. Dis. 2:339-342.[Medline]
  11. Courtney, H. S., D. L. Hasty, Y. Li, H. C. Chiang, J. L. Thacker, and J. B. Dale. 1999. Serum opacity factor is a major fibronectin-binding protein and a virulence determinant of M type 2 Streptococcus pyogenes. Mol. Microbiol. 32:89-98.[CrossRef][Medline]
  12. De Azavedo, J. C. S., R. H. Yeung, D. J. Bast, C. L. Duncan, S. B. Borgia, and D. E. Low. 1999. Prevalence and mechanisms of macrolide resistance in clinical isolates of goup A streptococci from Ontario, Canada. Antimicrob. Agents Chemother. 43:2144-2147.[Abstract/Free Full Text]
  13. Dicuonzo, G., G. Gherardi, G. Lorino, S. Angeletti, M. De Cesaris, E. Fiscarelli, D. E. Bessen, and B. Beall. 2001. Group A streptococcal genotypes from pediatric throat isolates in Rome, Italy. J. Clin. Microbiol. 39:1687-1690.[Abstract/Free Full Text]
  14. Enright, M. C., B. G. Spratt. A. Kalia, J. H. Cross, and D. E. Bessen. 2001. Multilocus sequence typing of Streptococcus pyogenes and the relationships between emm type and clone. Infect. Immun. 69:2416-2427.[Abstract/Free Full Text]
  15. Facinelli, B., C. Spinaci, G. Magi, E. Giovanetti, and P. Varaldo. 2001. Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci. Lancet 358:30-33.[CrossRef][Medline]
  16. Facklam, R., A. Efstratiou, P. Kriz, G. Tyrrell, M. Lovgren, T. Thompson, S. Gowan, D. Martin, E. Kaplan, and B. Beall. 2002. Continued extension of the Lancefield classification scheme for group A streptococci by addition of 22 new M protein gene sequence types: emm103 to emm124. Clin. Infect. Dis. 34:28-38.[CrossRef][Medline]
  17. Giovanetti, E., M. P. Montanari, M. Mingoia, and P. E. Varaldo. 1999. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains. Antimicrob. Agents Chemother. 43:1935-1940.[Abstract/Free Full Text]
  18. Hanski, E., and M. Caparon. 1992. Protein F, a fibronectin binding protein, is an adhesin of the group A streptococcus, Streptococcus pyogenes. Proc. Natl. Acad. Sci. USA 89:6172-6176.[Abstract/Free Full Text]
  19. Jasir, A., A. Tanna, A. Efstratiou, and C. Schalén. 2001. Unusual occurrence of M type 77, antibiotic-resistant group A streptococci in southern Sweden. J. Clin. Microbiol. 39:586-590.[Abstract/Free Full Text]
  20. Johnson, D. R., and E. L. Kaplan. 1993. A review of the correlation of T-agglutination patterns and M-protein typing and opacity factor production in the identification of group A streptococci. J. Med. Microbiol. 38:311-315.[Abstract]
  21. Kataja, J., P. Houvien, A. Moutiala, J. Vuopio-Varkila, A. Efstratiou, G. Hallas, and H. Seppälä. 1998. Clonal spread of group A streptococcus with the new type of erythromycin resistance. J. Infect. Dis. 177:786-789.[Medline]
  22. Kreikemeyer, B., S. R. Talay, and G. S. Chhatwal. 1995. Characterization of a novel fibronectin-binding surface protein in group A streptococci. Mol. Microbiol. 17:137-145.[Medline]
  23. Martin, J. M., M. Green, K. A. Barbadora, and E. R. Wald. 2002. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N. Engl. J. Med. 346:1200-1206.[Abstract/Free Full Text]
  24. Molinari, G., S. R. Talay, P. Valentin-Weigand, M. Rohde, and G. S. Chhatwal. 1997. The fibronectin-binding protein of Streptococcus pyogenes, SfbI, is invoved in the internalization of group A streptococci by epithelial cells. Infect. Immun. 65:1357-1363.[Abstract]
  25. National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial disk susceptibility tests. Approved standard, 7th ed. NCCLS document M2-A7. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  26. Neeman, R., N. Keller, A. Barzilai, Z. Korenman, and S. Sela. 1998. Prevalence of internalisation-associated gene, prtF1, among persisting group A streptococcus strains isolated from asymptomatic carriers. Lancet 352:1974-1977.[CrossRef][Medline]
  27. Palavecino, E. L., I. Riedel, X. Berrios, S. Bajaksouzian, D. Johnson, E. Kaplan, and M. R. Jacobs. 2001. Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Santiago, Chile. Antimicrob. Agents Chemother. 45:339-341.[Abstract/Free Full Text]
  28. Perez-Trallero, E., J. M. Marimon, M. Montes, B. Orden, and M. de Pablos. 1999. Clonal differences among erythromycin-resistant Streptococcus pyogenes in Spain. Emerg. Infect. Dis. 5:235-240.[Medline]
  29. Rakonjak, J. V., J. C. Robbins, and V. A. Fischetti. 1995. DNA sequence of the serum opacity factor of group A streptococci: identification of a fibronectin-binding repeat domain. Infect. Immun. 63:622-631.[Abstract]
  30. Ripa, S., C. Zampaloni, L. A. Vitali, E. Giovannetti, M. P. Montanari, M. Prenna, and P. E. Varaldo. 2000. SmaI macrorestriction analysis of Italian isolates of erythromycin-resistant Streptococcus pyogenes and correlation with macrolide-resistance phenotypes. Microb. Drug Resist. 7:65-71.
  31. Roberts, M. C., J. Sutcliffe, P. Courvalin, L. B. Jensen, J. Rood, and H. Seppälä. 1999. Nomenclature of macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother. 43:2823-2830.[Free Full Text]
  32. Savoia, D., C. Avanzini, K. Bosio, G. Volpe, D. Carpi, G. Dotti, and M. Zucca. 2000. Macrolide resistance in group A streptococci. J. Antimicrob. Chemother. 45:41-47.[Abstract/Free Full Text]
  33. Seppälä, H., A. Nissinen, Q. Yu, and P. Huovinen. 1993. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J. Antimicrob. Chemother. 32:885-891.[Free Full Text]
  34. Seppälä, H., M. Skurnik, H. Soini, M. C. Roberts, and P. Huovinen. 1998. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob. Agents Chemother. 42:257-262.[Abstract/Free Full Text]
  35. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.[Abstract]
  36. Sutcliffe, J., A. Tait-Kamradt, and L. Wondrack. 1996. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob. Agents Chemother. 40:1817-1824.[Abstract]
  37. Talay, S. R., P. Valentin-Weigand, P. G. Jerlström, K. N. Timmis, and G. S. Chhatwal. 1992. Fibronectin-binding protein of Streptococcus pyogenes: sequence of the binding domain involved in the adherence of streptococci to epithelial cells. Infect. Immun. 60:3837-3844.[Abstract/Free Full Text]
  38. Teixera, L. M., R. R. Barros, A. C. D. Castro, J. M. Peralta, M. D. G. S. Carvalho, D. F. Talkington, A. M. Vivoni, R. R. Facklam, and B. Beall. 2001. Genetic and phenotypic features of Streptococcus pyogenes strains isolated in Brazil that harbor new emm sequences. J. Clin. Microbiol. 39:3290-3295.[Abstract/Free Full Text]
  39. Varaldo, P. E., E. A. Debbia, G. Nicoletti, D. Pavesio, S. Ripa, G. C. Schito, and G. Tempera. 1999. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes. Clin. Infect. Dis. 29:869-873.[Medline]
  40. Weiss, K., J. De Azavedo, C. Restieri, L. A. Galarneau, M. Gourdeau, P. Harvey, J. F. Paradis, K. Salim, and D. E. Low. 2001. Phenotypic and genotypic characterization of macrolide-resistant group 28 A Streptococcus strains in the province of Quebec, Canada. J. Antimicrob. Chemother. 47:345-348.[Abstract/Free Full Text]
  41. Whatmore, A. M., V. Kapur, D. J. Sullivan, J. M. Musser, and M. A. Kehoe. 1994. Non-congruent relationships between variation in emm gene sequence and the population genetic structure of group A streptococci. Mol. Microbiol. 14:619-631.[Medline]
  42. Whatmore, A. M., and M. A. Kehoe. 1994. Horizontal gene transfer in the evolution of group A streptococcal emm-like genes: gene mosaics and variation in Vir regulons. Mol. Microbiol. 11:363-374.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, December 2002, p. 3987-3990, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.3987-3990.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dicuonzo, G.
Right arrow Articles by Beall, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dicuonzo, G.
Right arrow Articles by Beall, B.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS